Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate

Stock Information for Compugen Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compugen Ltd.

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
Compugen Reports Fourth Quarter and Full Year 2023 Results
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.